ArticleJournal of clinical medicine research2019

Differing Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Ipragliflozin on the Decrease of Fat Mass vs. Lean Mass in Patients With or Without Metformin Therapy.

Yoshio Nagai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.